한국임상수의학회지 (Journal of Veterinary Clinics)

  • 제17권2호
  • /
  • Pages.311-315
  • /
  • 2000
  • /
  • 1598-298X(pISSN)
  • /
  • 2384-0749(eISSN)
한국임상수의학회 (The Korean Society of Veterinary Clinics)
권호 표지

마우스에 있어서 Interleukin -2의 투여방법이 Meth-A 종양세포에 대한 항암효과에 미치는 영향

Effect of Interleukin-2 Administration Route on Antitumor Response Against Subcutaneous Meth-A Tumor in Mice

  • 권오덕 (전북대학교 수의과대학)
  • 발행 : 2000.12.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Recombinant interleukin-2 (IL-2) has been demonstated as an antineoplastic agent in mice and human, and the route of administration is important to IL-2-induced therapeutic responses. Therefore, the current experiment was undertaken to clarify the effect of IL-2 administration route on antitumor response against subcutaneous Meth-A tumor in mice. At the beginning of each experiment, normal BALB/c mice were injected subcutaneously with $5{\times}10^6$ Meth-A tumor cells. Beginning on day 7, experimental groups were treated with a 5-day course of IL-2 (intraperitoneal or subcutaneous injection of 30, 000 IU every 12 hours for 5 days). The result of this experiment revealed that Meth-A tumor grew progressively in control mice. Intraperitoneal IL-2 treatment decreased significantly tumor growth and prolonged survival, compared with control mice. Subcutaneous IL-2 treatment decreased significantly tumor growth until day 11 and tumor cells, grew progressively thereafter, but mice in this group survived longer than control mice.

키워드

참고문헌

  1. Clin Pharmacokinet v.27 Effects of route and formulation on clinical pharmacokinetics of interleukin-2 Anderson PM;Sorenson MA
  2. Br J Cancer v.75 Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2:evidence for non-renal clearance of cytokines Banks RE;Forbes MA;Hallam S;Jenkins A;Wadhwa M;Dilger P;Meager A;Thorpe R;Bowmer CJ;Joffe JK;Patel P;Johnson PW;Selby PJ
  3. Cancer Res v.50 Correlation between clinical response to interleukin-2 therapy and sustained production of tumor necrosis foctor Blay JY;Favrot MC;Negrier S;Combaret V;Chouaib S;Mercatello A;Kaemmerlen P;Franks CR;Phillip T
  4. Cancer Res v.50 Adoptive immunotherapy of human cancer.The cytokine cascade and monocyte activation following high-dose interleukin-2 bolus treatment Boccoli G;Masciulli R;Ruggeri EM;Carlini P;Giannella G;Montesoro E;Mastroberadino G;Isacchi G;Testa U;Calabresi F(et al.)
  5. Int J Cancer v.10 Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donors Borberg H;Octtgen HF;Choudry K;Beattie EJ
  6. Blood v.93 Interleukin-2-activated rat natural killer cells express inducible nitric oxide synthase that contributes to cytotoxic function and interferon-gamma production Cifone MG;D'Alo S;Parroni R;Millimaggi D;Biordi L;Martinotti S;Santoni A
  7. Clin Cancer Res v.6 Phase II trial of interleukin 2.interferon alpha, and 5-fluorouracil in metastatic renal cell cancer a cytokine working group study Dutcher JP;Logan T;Gordon M;Sosman J;Weiss G;Margolin K;Plasse T;Mier J;Lotze M;Clark J;Atkins M
  8. J.Immunother Emphasis Tumor Immunol v.19 Immunopharmacology and cytokine production of a low-dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma Freedman RS;Gibbons JA;Giedlin M;Kudelka AP;Kavanagh JJ;Edwards CL;Carrasco CH;Nash MA;Platsoucan CD
  9. Cancer Res v.48 Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin-2 and lymphokine-activated killer cells Gelmo BT;Palladino MA Jr;Jeffe HS;Espevik TP;Rayner AA
  10. Biochem Biophys Res Commun v.157 Nitric oxide A cytotoxic activated macrophage effector molecule Hibbs JB Jr;Taintor RR;Vavrin Z;Rachlin C
  11. J Clin Invest v.89 Evidence for cytokine inducible nitric oxide synthesis from Larginine in patients receiving interleukin-2 therapy Hibbs JB Jr;Westenfelder C;Taintor RR;Vavrin Z;Kablitz C;Baranowski RL;Ward JH;Menloce RL;McMurry MP;Kushner JP;Samlowski WE
  12. J Urol v.160 Nitric oxide synthase activity in human renal cell careinoma Jansson OT;Moreos E;Brundin L;Bergerheim US;Adolfsson J;Wiklund NP
  13. Scand J Immunol v.52 Interleukin-2-induced nitric oxide synthase and nuclear factor-kappa B activity in activated natural killer cells and the production of interferon-gamma Jyothi MD;Khar A
  14. J Immunol v.143 Induction of endogeneous cytokinc mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients Kasid A;Director EP;Rosenberg SA
  15. Hum Exp Toxicol v.14 Pharmacokinetic,pharmacodynamic, and pharmacotoxic profiles of recombinant-methionyl human interleukin-2[alanine-125](r-metHuIL-2[ala-125])following intravenous and subcutaneous administration in rats LeBel CP;Langlois L;Bell DP;Young JD;Kenney WC;Payne BJ;Sendelbach LE;Wong LC
  16. Anticancer Res v.20 Effect of GM-CSF and IL-2 co-expression on the anti-tumor immune response Lee SG;Heo DS;Yoon SJ;Jee YS;Kang JO;Kim K;Kim CD;Sung MW;Kim NK
  17. Cancer Res v.41 Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor Lotze MT;Grimn EA;Mazumder A;Strausser JI;Rosenberg SA
  18. Immunol v.172 Human interleukin-2 molecular biology,physiology and clinical possibilities Immunol Mertelsmann R;Welte K
  19. J Clin Immuno v.8 Induction of circulating tumor neerosis factor (TNFa)as the mochanism for the febrile response to interleukin-2(IL-2) in cancer patients Mier JW;Vachino G;Van Der Meer JWM;Numerof RP;Adams S;Cannon JG;Bernheim HA;Atkins MB;Parkinson DR;Dinarello CA
  20. T-cell-derived cytokines and their receptors.In:Fundamental immunology(3rd ed) Paul WE
  21. Pharmacother v.16 Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HTV-infected patients Piscitelli SC;Wells MJ;Metcalf JA;Baseler M;Stevens R;Davey RT Jr
  22. Postepy Hig Med Dosw v.49 Biological properties and therapeutic use of interleukin 2(IL-2) Robak T
  23. Ann Int Med v.108 New approach to the immunotherapy of cancer using interleukin-2 Rosenberg SA;Lotze MT;Mule JJ
  24. J Immunother v.18 Effectiveness and toxicity of protracted nitric oxide synthesis inhibition during IL-2 treatment of mice Samlowski WE;Yim CY;McGregor JR;Kwon OD;Gonzales S;Hibbs JB Jr
  25. Gynakol Geburshifliche Rundsch v.35 no.1 Animal experiment, phamacokinetic and clinical studies of intraperitoneal therapy with interleukin-2 (nII-2)in patients with ovarian carcinoma Schroder W;Schwulera U;Lissner R;Bender HG
  26. Chung Kuo Yao Li Hsuch Pao v.15 Pharmacokinetics and tissue distribution of human recombinant interleukin-2 in mice Tang ZM;Liu XW;Xu LP;Shan CW;Song QS
  27. Interleukin-2.In:The cytokine handbook Thomson A
  28. Drugs v.46 Interleukin-2.A review of its pharmacological properties and therapcutic use in patients with cancer Whittington R;Faulds D
  29. Korean J Intern Med v.11 Effects of nitric oxide (NO) synthesis inhibition on antitumor responses during interleukin-2 (IL-2) treatment of mice Yim CY;Lee CW;Choi SM;Park SS;Lee SJ;Kim JH;Song JS;Yoo WH;Kwak JY;Sohn MH
  30. J Immunol v.155 Nitric oxide synthesis contributes to IL-2 induced antitumor response against intraperitoneal Meth A tumor Yim CY;McGregor JR;Kwon OD;Bastian NR;Rees M;Mori M;Hibbs JB,JrSamlowski WE